Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Biogen (BIIB) stock in plain English

Free brief · no signupStart here
BIIBPublished Nov 13, 2026
Biogen Inc
Healthcare · Drug Manufacturers - General
Manufactures and sells specialized therapies for multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease.
Assets:
Solothurn biologics facilityLarge-scale cell-culture drug manufacturing site in Switzerland
RTP manufacturing campusTwo large biomanufacturing facilities located in North Carolina
7,500 employeesGlobal workforce focused on research, clinical trials, and commercial sales
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

48
OPS ScoreOperating finances
Latest quote
-1.70%$247.13
$36.53B
105.8×
$9.90B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 13, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was BIIB. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Biogen (BIIB) do?

Biogen Inc (BIIB) is a U.S.-listed company in Healthcare (Drug Manufacturers - General). What it does: Manufactures and sells specialized therapies for multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease. Specializes in developing and manufacturing prescription therapies targeting complex neurological and neurodegenerative. It is worth $36.53B on the market and sold $9.90B over the last year.

Market cap
$36.53B
P/E ratio
105.8×
Annual sales
$9.90B
Sector
Healthcare
Industry
Drug Manufacturers - General
Brief updated
Nov 13, 2026

Brands and businesses behind BIIB

  • Spinraza: Prescription treatment for spinal muscular atrophy sold directly to hospitals and specialty medical providers.
  • Skyclarys: Once-daily capsule for Friedreich's ataxia generating revenue through specialized pharmacy distribution channels.
  • Tysabri: Infusion therapy for severe multiple sclerosis sold to healthcare clinics and specialized infusion centers.
  • Tecfidera: Oral capsule for relapsing multiple sclerosis generating revenue through commercial prescription sales.
  • Vumerity: Prescription oral pill for relapsing multiple sclerosis that earns revenue through retail and specialty pharmacies.
  • Leqembi: Infusion drug for early Alzheimer's disease that generates revenue through a global profit-sharing partnership.

BIIB’s flags, in plain English

Each flag is a number from Biogen’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 13, 2026.

Wide Gross Margin

Gross margin of 64% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Stupid Cash

Can pay this year's bills 2 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Low debt

Low debt, only 41% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Priced for Perfection

Priced at 105.8 times its yearly profit, so a lot of growth is already expected. The share price already assumes strong results, so news that is merely good can still send it down.

1 more green flag and 1 more risk note open with the free trial. Try it free for 7 days.

Questions about BIIB

How big is Biogen?

Biogen’s market cap is $36.53B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $9.90B: what customers paid the company over the last year, before any costs.

What is BIIB’s P/E ratio?

BIIB’s P/E ratio is 105.8×. Investors pay about 105.8 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with BIIB?

Patent expirations and generic alternatives have eroded sales from older multiple sclerosis therapies such as Tecfidera. That is one risk on Biogen’s card. Its first risk flag is Priced for Perfection, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Biogen’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. BIIB’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card